Yahoo Finance [Yahoo! Finance]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
Jefferies highlighted challenges in the ongoing trials for head and neck cancer, with early data showing only modest differentiation from existing treatments like Keytruda, and noted that the company's cash reserves are projected to last only until the first quarter of 2026, which may hinder its ability to advance its clinical programs effectively. Was this helpful? Yes No What is Jefferies' new price target for Alx Oncology's stock, and how does it compare to the previous target? Jefferies reduced its price target for Alx Oncology's stock to 2, down from 12, reflecting tempered expectations for the company's near-term prospects. Was this helpful? Yes No What specific concerns does Jefferies have about Alx Oncology's clinical trials? Jefferies analysts noted that the study's objective response rate and progression-free survival appeared less compelling upon further analysis, and attributed the diminished efficacy in the later phases of the trial to inconsistencies
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology Holdings Inc. (NASDAQ: ALXO) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $2.00 price target on the stock, down previously from $12.00.MarketBeat
- ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers SymposiumGlobeNewswire
ALXO
Earnings
- 11/7/24 - Beat
ALXO
Sec Filings
- 12/6/24 - Form SCHEDULE
- 12/4/24 - Form 4
- 12/4/24 - Form 4
- ALXO's page on the SEC website